COVID-19 and cardiogenic shock. Different cardiovascular presentations with high mortality

Publication date: August 2020Source: Revista Española de Cardiología (English Edition), Volume 73, Issue 8Author(s): Ángel Sánchez-Recalde, Jorge Solano-López, Javier Miguelena-Hycka, Jesús Javier Martín-Pinacho, Marcelo Sanmartín, José L. Zamorano
Source: Revista Espanola de Cardiologia - Category: Cardiology Source Type: research

Related Links:

We present our initial experience managing children with coronavirus disease 2019–related acute myocardial injury. The 3 patients presented here represent a spectrum of the cardiac involvement noted in children with coronavirus disease 2019–related multisystem inflammatory syndrome, including myocarditis presenting as cardiogenic shock or heart failure with biventricular dysfunction, valvulitis, coronary artery changes, and pericardial effusion.
Source: Cardiology in Review - Category: Cardiology Tags: Invited Review Articles Source Type: research
An alarming increase in children presenting with fever, hyperinflammation, and multiorgan dysfunction frequently requiring intensive care has been observed after severe acute respiratory syndrome coronavirus 2 infection. The illness resembles Kawasaki disease (KD), with coronary dilatation and aneurysm occurring in some. However, the cardiovascular manifestations were typically on the severe end of the KD spectrum, with cardiogenic shock a common presentation together with other features. This led to defining a unique syndrome named multisystem inflammatory syndrome in children (MIS-C). In this issue of the JCI, Lee and Da...
Source: Journal of Clinical Investigation - Category: Biomedical Science Authors: Source Type: research
We present a case of cardiomyopathy due to possible COVID-19 resulting in cardiogenic shock.
Source: Journal of Cardiac Failure - Category: Cardiology Authors: Tags: 203 Source Type: research
ConclusionsThe findings in this case are unique as this is the first report on accumulated oxidized phospholipids (or their breakdown products) in myocardial and renal tissue in COVID ‐19. This highlights ferroptosis, proposed to detrimentally contribute to some forms of ischaemia–reperfusion injury, as a detrimental factor in COVID‐19 cardiac damage and multiple organ failure.
Source: ESC Heart Failure - Category: Cardiology Authors: Tags: Original Research Article Source Type: research
The global coronavirus disease 2019 (COVID-19) pandemic has captured the world's conscious thought in a way not experienced in most of our lifetimes. In a world where Presidents conduct foreign policy by Twitter, we are not lacking information volume. In medicine, our version of the gold standard for truth is two well-conducted randomised controlled trials with concordant results. With the pandemic impacting health services so rapidly, decisions about treatment options may be required well ahead of this level of certainty.
Source: European Respiratory Journal - Category: Respiratory Medicine Authors: Tags: Editorials Source Type: research
Recent studies on the Coronavirus Disease 2019 (COVID-19) pandemic caused by SARS-CoV-2 infection found that cardiac injury occurred in up to 30% of patients, and was associated with increased disease severity.1 Myocarditis, an inflammatory disease of the myocardium, has been proposed to account for a proportion of cardiac injury, in addition to systemic inflammation. Myocarditis is classified as acute, chronic or fulminant, the latter being a sudden, severe manifestation associated with acute heart failure, cardiogenic shock and life-threatening arrhythmias.
Source: Heart and Lung - Category: Intensive Care Authors: Source Type: research
ConclusionCOVID ‐19 is an evolving pandemic with predominate respiratory manifestations, however, due to the interaction with the cardiovascular system; cardiac manifestations/complications feature heavily in this disease, with cardiac biomarkers providing important prognostic information.
Source: Journal of Cardiac Surgery - Category: Cardiovascular & Thoracic Surgery Authors: Tags: REVIEW ARTICLE Source Type: research
We describe a patient with COVID-19, who presented with ST-elevation myocardial infarction and was treated with thrombolysis and anticoagulation. He was later found to have a significant persistent thrombus burden requiring thrombectomy and stent placement. Invasive hemodynamics on multiple high-dose pressers revealed a high cardiac output state with low systemic vascular resistance, consistent with distributive rather than cardiogenic shock. Our case illustrates that thrombolytic therapy alone may not be adequate in patients with STEMI and COVID-19, as well as the importance of early invasive hemodynamics in management of...
Source: Reviews in Cardiovascular Medicine - Category: Cardiology Tags: Rev Cardiovasc Med Source Type: research
Authors: Kim HN, Lee JH, Park HS, Yang DH, Jang SY, Bae MH, Cho Y, Chae SC, Lee YH Abstract A 60-year-old male patient with coronavirus disease-2019 showed new onset ST-segment elevation in V1-V2 leads on electrocardiogram and cardiac enzyme elevation in intensive care unit. He had a history of type 2 diabetes mellitus, hypertension, and dyslipidemia. He was receiving mechanical ventilation and veno-venous extracorporeal membrane oxygenation treatment for severe hypoxia. Two-D echocardiogram showed regional wall motion abnormalities. We performed primary percutaneous coronary intervention for acute myocardial infar...
Source: Journal of Korean Medical Science - Category: Biomedical Science Tags: J Korean Med Sci Source Type: research
Abstract The coronavirus disease 2019 (COVID-19), elicited by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection, is a pandemic public health emergency of global concern. Other than the profound severe pulmonary damage, SARS-CoV-2 infection also leads to a series of cardiovascular abnormalities, including myocardial injury, myocarditis and pericarditis, arrhythmia and cardiac arrest, cardiomyopathy, heart failure, cardiogenic shock, and coagulation abnormalities. Meanwhile, COVID-19 patients with preexisting cardiovascular diseases are often at a much higher risk of increased morbidity and mort...
Source: Biochemical Pharmacology - Category: Drugs & Pharmacology Authors: Tags: Biochem Pharmacol Source Type: research
More News: Cardiogenic Shock | Cardiology | Cardiovascular | COVID-19 | Heart